Understanding fat metabolism in people with lipoprotein lipase deficiency

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how lipoprotein lipase deficiency (LPLD) affects the metabolism of dietary fatty acids in the body. It involves three visits, including a screening and two metabolic studies where participants will consume a low-fat liquid meal. The studies will be conducted with and without an intravenous heparin treatment to assess its impact on fat metabolism. Advanced imaging and stable isotopic tracer methods will be used to gather data over a nine-hour period following the meal.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 8 healthy LPL-deficient individuals (LPLD subjects) with history of fasting TG \> 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;
* 8 control subjects (fasting glucose \< 5.6, 2-hour post 75g OGTT glucose \< 7.8 mmol/l and HbA1c \< 5.8%; fasting TG \< 1.5 mmol/l);
* age 18 to 75 yo;
* To be willing and able to adhere to the specifications of the protocol;
* To have signed an informed consent document indicating that they understood the purpose

Exclusion Criteria:

* age \< 18 yo;
* overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG
* Treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to affect lipid or carbohydrate metabolism (except statins, metformin, and other antihypertensive agents that can be safely interrupted);
* Treatment with anti-hypertensive medication (only for LPL-deficient individuals);
* presence of liver or renal disease; uncontrolled thyroid disorder;
* previous diagnosis of heparin-induced thrombocytopenia;
* Treatment with oral anticoagulation medication or platelet aggregation inhibiting drugs;
* A history of major hemorrhagic event;
* smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day;;
* Female of child-bearing potential who is pregnant, breast feeding or intends to become pregnant or pre-menopausal female with a positive serum pregnancy test at the time of enrollment.

Where it's running

• Centre de recherche du CHUS
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: André Carpentier — Université de Sherbrooke
• Study coordinator: Frédérique Frisch
• Email: frederique.frisch@usherbrooke.ca
• Phone: 819-346-1110- ext12394

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with Lysosomal Acid Lipase Deficiency

  This study is collecting information from people with Lysosomal Acid Lipase Deficiency to help improve their care and treatment.

  Recruiting at 104 sites Alexion Pharmaceuticals, Inc. · Phoenix, Arizona and 103 other locations · NCT01633489

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.